Omeros (OMER) Non-Current Debt (2010 - 2026)
Omeros (OMER) posted Non-Current Debt of $52.8 million for Q1 2026, up 2.82% sequentially from $51.4 million in Q4 2025, and down 40.37% YoY from $88.6 million in Q1 2025.
Omeros (OMER) Non-Current Debt (2010 - 2026) Analysis & Trends
Omeros has reported Non-Current Debt for 17 years, with the latest figure at $52.8 million in Q1 2026.
- Quarterly Non-Current Debt fell 40.37% year-over-year to $52.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.8 million (down 40.37% YoY) and the FY2025 annual result came in at $51.4 million, down 47.14% from the prior year.
- Non-Current Debt rose to $52.8 million in Q1 2026 per OMER's latest filing, from $51.4 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $314.8 million in Q3 2022 and troughed at $51.4 million in Q4 2025.
- A 5-year average of $167.4 million and a median of $155.3 million in 2024 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2022 and 2025: Non-Current Debt rose 0.58% in 2022, then slumped 58.51% in 2025.
- Over 5 years, Non-Current Debt stood at $220.9 million in 2022, then increased by 0.42% to $221.8 million in 2023, then sank by 56.19% to $97.2 million in 2024, then slumped by 47.14% to $51.4 million in 2025, then increased by 2.82% to $52.8 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $52.8 million, $51.4 million, and $72.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 42.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.03 Mn |
| Mar 31, 2026 | 52.81 Mn |
| Dec 31, 2025 | 51.36 Mn |
| Sep 30, 2025 | 72.08 Mn |
| Jun 30, 2025 | 87.31 Mn |
| Mar 31, 2025 | 88.56 Mn |
| Dec 31, 2024 | 97.18 Mn |
| Sep 30, 2024 | 92.43 Mn |
| Jun 30, 2024 | 94.51 Mn |
| Mar 31, 2024 | 213.46 Mn |
| Sep 30, 2023 | 221.83 Mn |
| Jun 30, 2023 | 221.52 Mn |
| Mar 31, 2023 | 221.21 Mn |
| Dec 31, 2022 | 220.91 Mn |
| Sep 30, 2022 | 314.82 Mn |
| Jun 30, 2022 | 314.36 Mn |
| Mar 31, 2022 | 313.90 Mn |
| Dec 31, 2021 | 313.46 Mn |
| Sep 30, 2021 | 313.02 Mn |
| Jun 30, 2021 | 312.59 Mn |